PMPatrick Ohiani Moru

Patrick Ohiani Moru

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrick Ohiani Moru has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Informed consent for somatic gene editing for sickle cell disease in sub-Saharan Africa: a scoping review

    by Patrick Ohiani Moru, Obiageli Eunice Nnodu, Victoria Nembaware, Reuben Ikechukwu Chianumba, Anthonia Chinenye Okoro, Arthemon Nguweneza, Maxwell Madueke Nwegbu, Ambroise Wonkam

    Somatic gene editing targets non-reproductive cells to treat genetic diseases like sickle cell disease (SCD) without affecting future generations. However, there are challenges in obtaining informed consent in sub-Saharan Africa (sSA) due to language barriers, cultural differences, and low health literacy. While promising, somatic gene editing carries risks such as off-target effects, unintended gene transfer, and potential activation of oncogenes. The aims of the review are to conduct an in-depth literature review of the current approaches to informed consent for somatic gene editing and gene therapy and identify potential areas for improvement, specifically in relation to SCD in sSA. Arksey and O’Malley five steps approach was adopted for this scoping review. A combined search via PubMed and EBSCOhost retrieved a total of 57 articles, Screening was conducted and a total of 23 articles were included in this review. Of the 23 articles 5 were original cross-sectional studies, 4 were reports, 10 were literature reviews, and 4 were opinion pieces, most of the articles were conducted in the USA (56.5%) and the least from Africa (4.3%). Themes included Patient Education, Risk Assessment, Paediatric Consideration, Ethical & Legal Consideration, Decision Making/Support, Privacy & Indemnification, Consenting process & Culture. In SSA, the consent process should use simple, clear language and visual aids for complex ideas, respect local customs and cultural norms and involve parents in decisions for children when appropriate. Privacy is a key concern, particularly due to stigmatization of genetic conditions like SCD. Informed consent is essential for gene therapy research in SCD in sSA. It is crucial to conduct a study to assess the level of gene therapy literacy among various stakeholders.

  • Open Access

    SickleInAfrica Consortium: A Seven-Country Study Evaluating the Performance of Dried Blood Spot Point-of-Care Testing in Newborn Screening for Sickle Cell Disease

    by Obiageli Eunice Nnodu, Wilson Mupfururirwa, Sarah Kiguli, Lulu Chirande, Boubacar Ali Toure, Fred Stephen Sarfo, Patience Kuona, Aldiouma Guindo, Andrew Louden, Arthemon Nguweneza, et al.

    Sickle cell disease (SCD) is caused by an inherited single-nucleotide substitution in both copies of the β-globin gene [HBB(Glu7Val)]. The sickle-cell mutation results in the production of an abnor...


  • Open Access

    Looking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa

    by Nchangwi Syntia Munung, Obiageli E. Nnodu, Patrick Ohiani Moru, Akpaka A. Kalu, Benido Impouma, Marsha J. Treadwell, Ambroise Wonkam

    Somatic gene therapy will be one of the most exciting practices of genetic medicine in Africa and is primed to offer a “new life” for persons living with sickle cell disease (SCD). Recently, successful gene therapy trials for SCD in the USA have sparked a ray of hope within the SCD community in Africa. However, the high cost, estimated to exceed 1.5 million USD, continues to be a major concern for many stakeholders. While affordability is a key global health equity consideration, it is equally important to reflect on other ethical, legal and social issues (ELSIs) that may impact the responsible implementation of gene therapy for SCD in Africa. These include informed consent comprehension, risk of therapeutic misestimation and optimistic bias; priorities for SCD therapy trials; dearth of ethical and regulatory oversight for gene therapy in many African countries; identifying a favourable risk-benefit ratio; criteria for the selection of trial participants; decisional conflict in consent; standards of care; bounded justice; and genetic tourism. Given these ELSIs, we suggest that researchers, pharma, funders, global health agencies, ethics committees, science councils and SCD patient support/advocacy groups should work together to co-develop: (1) patient-centric governance for gene therapy in Africa, (2) public engagement and education materials, and (3) decision making toolkits for trial participants. It is also critical to establish harmonised ethical and regulatory frameworks for gene therapy in Africa, and for global health agencies to accelerate access to basic care for SCD in Africa, while simultaneously strengthening capacity for gene therapy.